FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946967820> ?p ?o ?g. }

• W1946967820 endingPage "1009" @default.
• W1946967820 startingPage "1008" @default.
• W1946967820 abstract "In this issue of EBioMedicine, Naohisa Hosomi and colleagues report the eagerly awaited results of the Japan Statin Treatment Against Recurrent Stroke (J-STARS) trial (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). A total of 1578 Japanese men and women aged 45 to 80 years with previous non-cardioembolic ischaemic stroke and total cholesterol concentration between 4.65 and 6.21 mmol/l were randomly assigned to open-label pravastatin 10 mg per day or to control (no statin, but non-statin drugs were allowed) and followed for a mean of 4.9 years (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). Allocation to pravastatin was associated with a reduction in mean total cholesterol concentration by 0.57 mmol/l and low-density lipoprotein (LDL) cholesterol by 0.55 mmol/l compared to control, but no difference in the primary endpoint of stroke or TIA (2.56% vs 2.65% per year, adjusted hazard ratio [HR] 0.97, 95% confidence interval [CI]: 0.73 to 1.29) (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). Allocation to pravastatin was however associated with a lower incidence of ischaemic stroke due to atherothrombosis compared to control (0.21% vs 0.64% per year, adjusted HR 0.33, 0.15 to 0.74) without increasing intracranial haemorrhage (0.29% vs 0.31% per year, adjusted HR 1.00, 0.45 to 2.22) or mortality (1.11% vs 0.90% per year, adjusted HR 1.23, 0.79 to 1.93) (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). The J-STARS trial provides novel data about the safety and efficacy of statins in preventing recurrent stroke in Japanese (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). Although statins have been shown conclusively to reduce the risk of stroke by one sixth (risk ratio [RR]: 0.85, 95% CI: 0.80–0.89) for every 1.0 mmol/l reduction in LDL cholesterol in 174,000 participants enrolled in 27 randomised trials (Cholesterol Treatment Trialists' (CTT) Collaboration, 2015Cholesterol Treatment Trialists' (CTT) CollaborationEfficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet. 2015; 385: 1397-1405Summary Full Text Full Text PDF PubMed Scopus (885) Google Scholar), it has been uncertain whether these results can be generalised to individuals with a history of prior stroke. There have been only 5 randomised controlled trials of statins in patients with prior stroke or TIA (total n = 9224) and the estimate of efficacy in preventing recurrent stroke is marginal (10.8% statin vs 12.1% control; odds ratio [OR]: 0.88, 95% CI: 0.77 to 1.00) (Manktelow and Potter, 2009Manktelow B.N. Potter J.F. Interventions in the management of serum lipids for preventing stroke recurrence.Cochrane Database Syst. Rev. 2009; 3: CD002091https://doi.org/10.1002/14651858.CD002091.pub2Crossref PubMed Scopus (75) Google Scholar). In the two trials that recorded the pathological subtype of stroke outcome events, allocation to statins (simvastatin 40 mg daily (Heart Protection Study Collaborative Group, 2004Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions.Lancet. 2004; 363: 757-767Summary Full Text Full Text PDF PubMed Scopus (973) Google Scholar) or atorvastatin 80 mg daily (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) InvestigatorsHigh-dose atorvastatin after stroke or transient ischemic attack.N. Engl. J. Med. 2006; 355: 549-559Crossref PubMed Scopus (2314) Google Scholar)) was associated with a significant reduction in ischaemic stroke (7.9% statin vs 9.9% control; OR 0.78, 0.67 to 0.92) but also a significant increase in haemorrhagic stroke (1.9% statin vs 1.1%; OR 1.72, 1.20 to 2.46) (Manktelow and Potter, 2009Manktelow B.N. Potter J.F. Interventions in the management of serum lipids for preventing stroke recurrence.Cochrane Database Syst. Rev. 2009; 3: CD002091https://doi.org/10.1002/14651858.CD002091.pub2Crossref PubMed Scopus (75) Google Scholar). As the incidence of haemorrhagic stroke in Japan is twice that observed in Western countries (Suzuki and Izumi, 2015Suzuki K. Izumi M. The incidence of hemorrhagic stroke in Japan is twice compared with Western countries: the Akita Stroke Registry.Neurol. Sci. 2015; 36: 155-160Crossref PubMed Scopus (18) Google Scholar), where previous trials in stroke patients were undertaken (Heart Protection Study Collaborative Group, 2004Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions.Lancet. 2004; 363: 757-767Summary Full Text Full Text PDF PubMed Scopus (973) Google Scholar, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) InvestigatorsHigh-dose atorvastatin after stroke or transient ischemic attack.N. Engl. J. Med. 2006; 355: 549-559Crossref PubMed Scopus (2314) Google Scholar), another uncertainty and concern have been whether statins are safe in Japanese with a history of prior stroke. The only previous randomised controlled trial of a statin in Japanese was the Management of Elevated cholesterol in the primary prevention Group of Adult Japanese (MEGA) trial in 7832 Japanese men and women with hypercholesterolaemia (total cholesterol 5.69–6.98 mmol/l) and no history of stroke (Nakamura et al., 2006Nakamura H. Arakawa K. Itakura H. Kitabatake A. Goto Y. Toyota T. et al.for the MEGA Study GroupPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.Lancet. 2006; 368: 1155-1163Summary Full Text Full Text PDF PubMed Scopus (733) Google Scholar). Pravastatin 10–20 mg daily reduced the risk of coronary heart disease (primary outcome) by one third (HR 0.67, 95% CI 0.49 to 0.9) compared to control but did not have a significant effect on any first-ever stroke (2.5% vs 3.0%, HR 0.83, 95% CI: 0.57 to 1.21). There was however, a trend toward a reduction in ischaemic stroke (1.7% vs 2.2%; HR 0.76, 95% CI: 0.49 to 1.18) and increase in intracranial haemorrhage (0.8% vs 0.7%; HR: 1.8, 0.58 to 2.42) with pravastatin compared to control, as observed in the two previous trials of statins in patients with prior stroke (Heart Protection Study Collaborative Group, 2004Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions.Lancet. 2004; 363: 757-767Summary Full Text Full Text PDF PubMed Scopus (973) Google Scholar, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) InvestigatorsHigh-dose atorvastatin after stroke or transient ischemic attack.N. Engl. J. Med. 2006; 355: 549-559Crossref PubMed Scopus (2314) Google Scholar; Suzuki and Izumi, 2015Suzuki K. Izumi M. The incidence of hemorrhagic stroke in Japan is twice compared with Western countries: the Akita Stroke Registry.Neurol. Sci. 2015; 36: 155-160Crossref PubMed Scopus (18) Google Scholar). The results of the J-STARS trial will reassure clinicians about the safety of pravastatin 10 mg per day in Japanese patients with prior ischaemic stroke. However, they raise questions about the efficacy of pravastatin 10 mg daily in preventing stroke or TIA (HR 0.97, 0.73 to 1.29) and any stroke (2.35% vs 2.47% per year, adjusted HR 0.95, 0.71 to 1.28). The failure to prove the efficacy of pravastatin may have several explanations. First, the study was underpowered to reliably identify or exclude a modest but clinically significant effect of pravastatin because it only recruited about half (n = 1578) of the initial target sample size of 3000 and the outcome event rate was lower than expected. Hence, the estimates are prone to substantial random error as indicated by their wide 95% confidence intervals. Second, the dose of pravastatin (10 mg per day) and degree of reduction in LDL cholesterol compared to control (0.55 mmol/l) may have been too small to generate a detectable treatment effect, given that higher doses of pravastatin (40 mg per day) and greater reductions in LDL cholesterol (≥1.0 mmol/l) have been associated with efficacy (White et al., 2000White H.D. Simes R.J. Anderson N.E. Hankey G.J. Watson J.D. Hunt D. et al.Pravastatin therapy and the risk of stroke.N. Engl. J. Med. 2000; 343: 317-326Crossref PubMed Scopus (310) Google Scholar, Cholesterol Treatment Trialists' (CTT) Collaboration, 2010Cholesterol Treatment Trialists' (CTT) CollaborationEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681Summary Full Text Full Text PDF PubMed Scopus (4511) Google Scholar). Third, pravastatin may only be effective in preventing one aetiological subtype of ischaemic stroke — atherothrombotic, as suggested by a subgroup analysis of the J-STARS results (Hosomi et al., in pressHosomi N. Nagai Y. Kohriyama T. Ohtsuki T. Aoki A. Nezu T. et al.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicentre, randomized, open-label, parallel group study.EBioMedicine. 2015; 2: 1071-1078Summary Full Text Full Text PDF Scopus (74) Google Scholar). However, although this subgroup analysis was pre-specified, the results are only hypothesis-generating. It now behoves researchers to explore the hypothesis that more intense reductions in LDL-cholesterol by higher doses of statins (and other lipid-lowering interventions, such as anti-PCSK9 antibodies (Zhang et al., 2015Zhang X.L. Zhu Q.Q. Zhu L. Chen J.Z. Chen Q.H. Li G.N. et al.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.BMC Med. 2015; 13: 123Crossref PubMed Scopus (195) Google Scholar)) may be safe and effective in preventing recurrent ischaemic stroke due to atherothrombosis, and recurrent stroke of any type, in Japanese patients with recent non-cardioembolic ischaemic stroke and a wide range of LDL cholesterol concentrations. None. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group StudyAlthough whether low-dose pravastatin prevents recurrence of total stroke or TIA still needs to be examined in Asian, this study has generated a hypothesis that it may reduce occurrence of stroke due to larger artery atherosclerosis. Full-Text PDF Open Access" @default.
• W1946967820 created "2016-06-24" @default.
• W1946967820 creator A5014800121 @default.
• W1946967820 date "2015-09-01" @default.
• W1946967820 modified "2023-10-14" @default.
• W1946967820 title "The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Trial: Where to Now?" @default.
• W1946967820 cites W1546258268 @default.
• W1946967820 cites W1890541571 @default.
• W1946967820 cites W1922625321 @default.
• W1946967820 cites W2015137536 @default.
• W1946967820 cites W2045925488 @default.
• W1946967820 cites W2097571126 @default.
• W1946967820 cites W2126678006 @default.
• W1946967820 cites W2164089346 @default.
• W1946967820 cites W2200285648 @default.
• W1946967820 cites W2917267661 @default.
• W1946967820 doi "https://doi.org/10.1016/j.ebiom.2015.08.007" @default.
• W1946967820 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4588442" @default.
• W1946967820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26501089" @default.
• W1946967820 hasPublicationYear "2015" @default.
• W1946967820 type Work @default.
• W1946967820 sameAs 1946967820 @default.
• W1946967820 citedByCount "0" @default.
• W1946967820 crossrefType "journal-article" @default.
• W1946967820 hasAuthorship W1946967820A5014800121 @default.
• W1946967820 hasBestOaLocation W19469678201 @default.
• W1946967820 hasConcept C126322002 @default.
• W1946967820 hasConcept C127413603 @default.
• W1946967820 hasConcept C2776839432 @default.
• W1946967820 hasConcept C2779473830 @default.
• W1946967820 hasConcept C2780645631 @default.
• W1946967820 hasConcept C2910980524 @default.
• W1946967820 hasConcept C55493867 @default.
• W1946967820 hasConcept C71924100 @default.
• W1946967820 hasConcept C78519656 @default.
• W1946967820 hasConcept C86803240 @default.
• W1946967820 hasConceptScore W1946967820C126322002 @default.
• W1946967820 hasConceptScore W1946967820C127413603 @default.
• W1946967820 hasConceptScore W1946967820C2776839432 @default.
• W1946967820 hasConceptScore W1946967820C2779473830 @default.
• W1946967820 hasConceptScore W1946967820C2780645631 @default.
• W1946967820 hasConceptScore W1946967820C2910980524 @default.
• W1946967820 hasConceptScore W1946967820C55493867 @default.
• W1946967820 hasConceptScore W1946967820C71924100 @default.
• W1946967820 hasConceptScore W1946967820C78519656 @default.
• W1946967820 hasConceptScore W1946967820C86803240 @default.
• W1946967820 hasIssue "9" @default.
• W1946967820 hasLocation W19469678201 @default.
• W1946967820 hasLocation W19469678202 @default.
• W1946967820 hasLocation W19469678203 @default.
• W1946967820 hasLocation W19469678204 @default.
• W1946967820 hasLocation W19469678205 @default.
• W1946967820 hasOpenAccess W1946967820 @default.
• W1946967820 hasPrimaryLocation W19469678201 @default.
• W1946967820 hasRelatedWork W1966939585 @default.
• W1946967820 hasRelatedWork W1991178429 @default.
• W1946967820 hasRelatedWork W2049567231 @default.
• W1946967820 hasRelatedWork W2127649116 @default.
• W1946967820 hasRelatedWork W2412969466 @default.
• W1946967820 hasRelatedWork W2673941008 @default.
• W1946967820 hasRelatedWork W2742054955 @default.
• W1946967820 hasRelatedWork W2959327971 @default.
• W1946967820 hasRelatedWork W2964357718 @default.
• W1946967820 hasRelatedWork W4255671940 @default.
• W1946967820 hasVolume "2" @default.
• W1946967820 isParatext "false" @default.
• W1946967820 isRetracted "false" @default.
• W1946967820 magId "1946967820" @default.
• W1946967820 workType "article" @default.